167 related articles for article (PubMed ID: 31629989)
1. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
[TBL] [Abstract][Full Text] [Related]
3. Comparison of three commercially available ELISA assays for anti-infliximab antibodies.
West TA; Sam M; Toong C
Pathology; 2021 Jun; 53(4):508-514. PubMed ID: 33272693
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
7. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
Rissel F; Cazaubon Y; Saffar S; Altwegg R; Artasone M; Lozano C; Vincent T; Jentzer A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373525
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
11. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels.
Pérez I; Fernández L; Sánchez-Ramón S; Alba C; Zatarain A; Cañas M; López ON; Olivares D; Rey E; Taxonera C
Therap Adv Gastroenterol; 2018; 11():1756284818783613. PubMed ID: 30034528
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
Jukic T; Drobne D; Pusavec S; Ihan A; Stubljar D; Starc A
Med Sci Monit; 2023 Feb; 29():e939084. PubMed ID: 36807319
[TBL] [Abstract][Full Text] [Related]
13. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
14. Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies.
Sam MJ; Connor SJ; Ng WW; Toong CM
Ther Drug Monit; 2020 Dec; 42(6):821-828. PubMed ID: 32947553
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.
Hernández-Flórez D; Valor L; de la Torre I; Nieto JC; Martínez-Estupiñán L; González C; López-Longo FJ; Monteagudo I; Garrido J; Naredo E; Carreño L
Rheumatol Int; 2015 Jun; 35(6):1021-5. PubMed ID: 25410014
[TBL] [Abstract][Full Text] [Related]
16. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Marín-Jiménez I; Menchén LA; López-Cauce B; López-Fernández LA; Lucendo AJ
J Pharm Biomed Anal; 2021 May; 198():114003. PubMed ID: 33714800
[TBL] [Abstract][Full Text] [Related]
18. Comparison of infliximab drug measurement across three commercially available ELISA kits.
Lee MW; Connor S; Ng W; Toong CM
Pathology; 2016 Oct; 48(6):608-12. PubMed ID: 27567230
[TBL] [Abstract][Full Text] [Related]
19. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
Valdés-Delgado T; Aguado-Paredes A; Merino-Bohórquez V; Martín-Manzanares J; Alonso MM; Maldonado B; Castro L; Belvis M; Benítez B; Caunedo Á; Calleja MÁ; Argüelles-Arias F
Dig Dis Sci; 2024 Jan; 69(1):228-234. PubMed ID: 37943382
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Arias-González L; Ruiz-Ponce M; Menchén LA; Sánchez C; López-Fernández LA; Lucendo AJ
Clin Chem Lab Med; 2019 Nov; 57(12):1906-1914. PubMed ID: 31085742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]